

# Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials / Institute of Neuromodulation / International Neuromodulation Society

# RESEARCH DESIGN CONSIDERATIONS FOR RANDOMIZED CLINICAL TRIALS OF SPINAL CORD STIMULATION FOR PAIN NOVEMBER 14-16, 2018 WESTIN GEORGETOWN, WASHINGTON, DC

#### **AGENDA**

## Wednesday, November 14, 2018

7:00 – 9:00 PM Welcome Reception/Dinner Location: Mayfair Court

## Thursday, November 15, 2018

7:15-8:00 AM	Breakfast Location: Washington Ballroom Foyer
8:00-8:15 am	<ul> <li>Welcome and introductions</li> <li>Location: Washington Ballroom</li> <li>Richard North, MD, Simon Thomson, MD, and Dennis Turk, PhD</li> </ul>
8:15-9:00 ам	The history of research on the mechanisms, efficacy, and safety of spinal cord stimulation  • Richard North, MD
9:00-9:45 ам	SCS clinical trial objectives and research designs, including comparison groups and testing superiority vs. non-inferiority  Rod Taylor, PhD
9:45-10:15 AM	Sources of bias in RCTs of SCS and their mitigation  Nathaniel Katz, MD
10:15-10:45 AM	Break
10:45-11:15 AM	Evidence standards for device approval: regulatory

Carlos Peña, PhD (CDRH)Rahul Singh, MD (MHRA)

perspectives

11:15 ам -12:30 рм	<ul> <li>Group discussion: study objectives, designs, and bias</li> <li>Moderators: Salim Hayek, MD, and Nathaniel Katz, MD</li> <li>Panelists: Richard North, MD; Carlos Peña, PhD; Rahul Singh, MD; Rod Taylor, PhD</li> </ul>
12:30-1:30 РМ	Lunch Location: Mayfair Court
1:30-2:00 РМ	Systematic review of methodologic characteristics and outcomes in RCTs of SCS for pain  • Ewan McNicol, PharmD
2:00-2:30 рм	Inclusion/exclusion criteria (e.g., diagnoses, pain severity, pain duration, psychosocial vulnerabilities; treatment history, concomitant analgesics)  • John Markman, MD
2:30-3:00 РМ	Primary and secondary outcomes (e.g., pain, function, opioid sparing; duration of follow up)  • Ali Rezai, MD
3:00-3:30 РМ	Break
3:30-4:00 РМ	Adverse events: assessment and reporting <ul><li>Salim Hayek, MD</li></ul>
4:00-5:30 рм	<ul> <li>Group discussion: inclusion/exclusion criteria, outcomes, and safety</li> <li>Moderator: Nathaniel Katz, MD, and Richard North, MD</li> <li>Panelists: Salim Hayek, MD; John Markman, MD; Ewan McNicol, PharmD; Ali Rezai, MD</li> </ul>
7:00 — 9:00 рм	<b>Dinner</b> Location: Thomas Boardroom
Friday, November 16, 2018	
7:15-8:00 AM	Breakfast Location: Washington Ballroom Foyer
8:00-8:30 ам	Study execution (e.g., controlling non-specific factors; programming standards; sponsor involvement; site and patient training; outcome assessment procedures)  Location: Washington Ballroom

• Simon Thomson, MD

8:30-9:00 AM	Data analysis, interpretation, and reporting (e.g., prespecification, estimands, missing data, multiplicity, clinical meaningfulness; responder definitions; "discerning hype from substance")  • Jennifer Gewandter, PhD
9:00-9:30 am	Economic outcomes and cost-effectiveness analyses  • Brian Kopell, MD
9:30-10:00 AM	Special issues in RCTs of SCS, including sham stimulation and programming comparisons  • Sam Eldabe, MD
10:00-10:30 ам	Break
10:30 ам -12:00 рм	<ul> <li>Group discussion: study execution, analysis, interpretation and reporting</li> <li>Moderator: Nathaniel Katz, MD, and Ali Rezai, MD</li> <li>Panelists: Sam Eldabe, MD; Jennifer Gewandter, PhD; Brian Kopell, MD; Simon Thomson, MD</li> </ul>
12:00-1:30 РМ	Lunch Location: Thomas Boardroom
1:30-4:00 РМ	Group discussion: recommendations for research methods, study execution, and reporting of RCTs of SCS Location: Washington Ballroom  • Moderators: Robert Dworkin, PhD, Nathaniel Katz, MD, and Rod Taylor, PhD
4:00 рм -	Departures